Ovarian Cancer

In the KEYNOTE-100 study, presented during the ASCO2020 Virtual Scientific Program, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, showed pembrolizumab had a modest but durable impact on recurrent ovarian cancer.

The COVID-19 pandemic greatly affected the delivery of cancer care across the U.S. and globally. In response, oncology societies have established guidance for clinicians on how to best manage ovarian cancer during the COVID-19 era.

Lipophilic statins appeared associated with reduced mortality among women with ovarian cancer, according to results of a retrospective study presented at American Association for Cancer Research Virtual Annual Meeting II.

Secondary cytoreductive surgery significantly increased PFS among a cohort of women with recurrent ovarian cancer, according to results of a randomized, phase 3 study presented during the ASCO20 Virtual Scientific Program.

Secondary cytoreductive surgery conferred significant and clinically meaningful OS and PFS benefits for selected women with recurrent ovarian cancer, according to phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Maintenance therapy with olaparib extended OS compared with placebo among women with platinum-sensitive, BRCA-mutated relapsed ovarian cancer, according to the final analysis of the randomized phase 3 SOLO-2 study scheduled for presentation during the ASCO20 Virtual Scientific Program.

During the COVID-19 pandemic, physicians across the United States have reported seeing fewer patients, who are fearful of presenting to the office due to the virus.

The FDA expanded the approval of olaparib to include its use in combination with bevacizumab for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.

Healio spoke with Naoko Sasamoto, MD, MPH, from the Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Harvard Medical School, about her JAMA Oncology study that suggested breastfeeding as a potentially modifiable factor that may decrease risk for ovarian cancer independent of pregnancy alone – and what this means for clinicians.

The FDA approved niraparib for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.